Early diagnosis of melanoma remains extremely challenging. Currently there are no validated blood-based biomarkers for early diagnosis. Therefore, a reliable screening test is an unmet medical need. Autoantibodies are emerging as promising biomarkers for early cancer detection. In a proof of principle experiment we identified five autoantibodies that provide 95% sensitivity / specificity. Now we will confirm and validate our findings and develop a clinical test for melanoma diagnosis.
Liquid Biopsy For Personalised Monitoring Of Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$820,888.00
Summary
Despite the success of recent melanoma treatments, therapies are effective long term in only a proportion of patients. Here we will progress preliminary findings in collaboration with biotechnology and pathology companies to develop highly effective companion biomarkers that will aid treatment decisions throughout disease course. Our team will spearhead translation of these markers into the clinic for routine monitoring of melanoma patients.
Enhancing Aspects Of Time-to-event Analysis Methodology In Randomised Trials
Funder
National Health and Medical Research Council
Funding Amount
$548,446.00
Summary
Time-to-event analysis is a statistical method for examining the occurrence of disease-related events in individuals followed for varying periods of time. The method is widely used in health research. The technicalities of the methods are subtle and by paying careful attention to these this grant will provide extended methods, new software, and apply methods more effectively to gain new insights to disease progress, and to enhance the efficiency of health research.
Role Of Resident Endothelial Progenitor Cells In Melanoma Vascularisation And Progression
Funder
National Health and Medical Research Council
Funding Amount
$952,328.00
Summary
Melanoma is one of the most frequent cancers in Australia. Its growth depends on the rpoper delivery of nutrients and oxygen through blood vessels. This requires the formation of new blood vessels as the tumour grows. In this project we intend to understand the origin of the blood vessels that form in tumours and identify the stem cells that support them. We will use proof of principle experiments to determine whether removal of these stem cells allows the regression of melanoma tumours.
The Role Of Force-sensing Ion Channels In Melanoma Migration
Funder
National Health and Medical Research Council
Funding Amount
$553,848.00
Summary
Metastasis of melanoma cells away from the primary tumour site carries a very poor patient prognosis.This research aims to characterise a novel signalling pathway that can regulate the migration (movement) of melanoma cells. This signalling pathway depends on force-sensing platforms that can rapidly convert physical inputs from the environment into an electrical signal within the cell. We are working to understand how these force-sensors function.
The Role Of Melanoma Tumour Antigen P97 (Melanotransferrin) In Melanoma Tumourigenesis.
Funder
National Health and Medical Research Council
Funding Amount
$563,242.00
Summary
The Role of Melanoma Tumour Antigen p97 (Melanotransferrin) in Melanoma Tumourigenesis Melanotransferrin (MTf) is a homologue of the iron transport protein, transferrin, and was one of the first well characterised melanoma tumour antigens. Our published studies have shown that MTf plays an important role in melanoma tumourigenesis in vivo. In this proposal, we will assess if it is associated with melanoma progression in patient samples and examine its role in melanoma growth and metastasis.
Centre Of Research Excellence In Melanoma: Person, Tumour And System-focussed Knowledge To Drive Better Outcomes In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$2,486,945.00
Summary
This Centre for Research Excellence in Melanoma will address three pivotal questions: how best to identify and conduct surveillance of the person with a high risk of melanoma, how best to manage the person who has developed a melanoma with high potential for relapse, and how best to improve support, survivorship and the patient experience. Economic evaluation, policy and implementation research are integral to the research plan.
Improving Skin Cancer Prevention: Motivating Preventive Behaviours Using Knowledge Of Personalised Genomic Risk Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$1,041,720.00
Summary
The aim of our study is to evaluate whether we can improve the Australian public’s skin cancer prevention behaviours, particularly reducing exposure to ultraviolet (UV) radiation, by giving personalised information about melanoma genetic risk. We will also explore the psycho-social, ethical, and economic implications of receiving this information. The results of our study are likely to influence the future of skin cancer prevention in Australia.
Which Modifiable Risk Factors Actually Cause Cancer?
Funder
National Health and Medical Research Council
Funding Amount
$384,076.00
Summary
Observational studies suggest that modifiable risk factors such as low vitamin D levels, coffee consumption, alcohol consumption and obesity may be important in cancer risk. However, observational studies can only demonstrate association between a risk factor and cancer, and association does not equal causation. We present an alternative approach to help determine which risk factors actually cause cancer.
Melanoma Mutation Profiling For Personalised Treatment
Funder
National Health and Medical Research Council
Funding Amount
$571,191.00
Summary
Melanoma is an aggressive skin cancer, and the leading cause of skin cancer related deaths. Disease spread is difficult to detect and extremely difficult to cure. This bleak clinical outcome is changing with the development of personalised therapies which include small molecule inhibitors to treat metastatic melanoma. Here we seek to identify the spectrum of mutations in patient tumours and circulating tumour cells for advanced personalised treatment.